FRED HUTCHINSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Employees: -

Market Cap: -

Website: https://www.fredhutch.org

Clinical Trials

MsFLASH-04: Pilot Trial: Telephone Behavioral Therapy for Menopause-related Sleep Disturbance

Not Applicable

Completed

Conditions: Vasomotor Disturbance
Hot Flashes
Menopause
Sleep

Interventions: Behavioral: Cognitive Behavioral Therapy-Insomnia (CBT-I)
Behavioral: Menopause Education Control (MEC)

First Posted Date: 2013-09-06

Last Posted Date: 2015-10-22

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 106

Registration Number: NCT01936441

Locations: 🇺🇸
University of Washington, Seattle, Washington, United States

Associations Between Pre-transplant Comorbidities and Post-transplant Toxicities and Quality of Life

Completed

Conditions: Hematologic Malignancies
Other Diagnoses, Comorbidities, and Complications

First Posted Date: 2013-08-29

Last Posted Date: 2018-01-11

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 252

Registration Number: NCT01930981

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Feasibility and Outcomes of Allogeneic HCT Compared to Chemotherapy in Older AML Patients

Completed

Conditions: Myelodysplastic Syndrome (MDS)
Acute Myeloid Leukemia (AML)

First Posted Date: 2013-08-28

Last Posted Date: 2019-11-15

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 703

Registration Number: NCT01929408

Locations: 🇺🇸
Stanford Cancer Institute, Stanford, California, United States
🇺🇸
University of Maryland, Baltimore, Maryland, United States
🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

and more 9 locations

Radiolabeled Monoclonal Antibody and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With High-Risk Lymphoid Malignancies

Phase 1

Completed

Conditions: Refractory Hodgkin Lymphoma
Recurrent Hodgkin Lymphoma
Refractory T-Cell Non-Hodgkin Lymphoma
Recurrent B-Cell Non-Hodgkin Lymphoma
Recurrent T-Cell Non-Hodgkin Lymphoma
Refractory Mantle Cell Lymphoma
Recurrent Mantle Cell Lymphoma
Refractory B-Cell Non-Hodgkin Lymphoma

Interventions: Procedure: Autologous Hematopoietic Stem Cell Transplantation
Drug: Carmustine
Drug: Cytarabine
Drug: Etoposide
Other: Laboratory Biomarker Analysis
Drug: Melphalan
Procedure: Peripheral Blood Stem Cell Transplantation
Radiation: Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8

First Posted Date: 2013-08-13

Last Posted Date: 2020-08-04

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 20

Registration Number: NCT01921387

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Chronic GVHD Response Measures Validation

Active, not recruiting

Conditions: Graft vs Host Disease

First Posted Date: 2013-07-18

Last Posted Date: 2024-03-26

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 383

Registration Number: NCT01902576

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Treo/Flu/TBI With Donor Stem Cell Transplant for Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia

Phase 2

Conditions: Acute Myeloid Leukemia in Remission
Myelodysplastic Syndrome
Chronic Myelomonocytic Leukemia
Minimal Residual Disease
Myelodysplastic/Myeloproliferative Neoplasm
Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable

Interventions: Procedure: Allogeneic Bone Marrow Transplantation
Drug: Fludarabine Phosphate
Procedure: Peripheral Blood Stem Cell Transplantation
Drug: Treosulfan
Radiation: Total-Body Irradiation
Other: Laboratory Biomarker Analysis

First Posted Date: 2013-07-10

Last Posted Date: 2021-06-03

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 102

Registration Number: NCT01894477

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

CYT107 After Vaccine Treatment (Provenge®) in Patients With Metastatic Castration-Resistant Prostate Cancer

Phase 2

Completed

Conditions: Castration Levels of Testosterone
Castration-Resistant Prostate Carcinoma
Metastatic Prostate Carcinoma
Stage IV Prostate Cancer

Interventions: Biological: Glycosylated Recombinant Human Interleukin-7
Other: Laboratory Biomarker Analysis

First Posted Date: 2013-06-20

Last Posted Date: 2019-07-09

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 54

Registration Number: NCT01881867

Locations: 🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
UCSF Medical Center-Mount Zion, San Francisco, California, United States
🇺🇸
UCSF Medical Center-Mission Bay, San Francisco, California, United States

and more 13 locations

Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia

Phase 1

Completed

Conditions: Refractory Mantle Cell Lymphoma
Refractory Non-Hodgkin Lymphoma
CD19-Positive Neoplastic Cells Present
Recurrent Non-Hodgkin Lymphoma
Recurrent Chronic Lymphocytic Leukemia
Recurrent Diffuse Large B-Cell Lymphoma
Recurrent Mantle Cell Lymphoma
Recurrent Small Lymphocytic Lymphoma
Refractory Acute Lymphoblastic Leukemia
Refractory Chronic Lymphocytic Leukemia

Interventions: Biological: Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes

First Posted Date: 2013-05-31

Last Posted Date: 2022-05-25

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 204

Registration Number: NCT01865617

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts in Preventing GVHD in Children

Phase 2

Completed

Conditions: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Acute Biphenotypic Leukemia
Acute Undifferentiated Leukemia
Adult Acute Lymphoblastic Leukemia in Remission
Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Recurrent Adult Acute Lymphoblastic Leukemia
Refractory Childhood Acute Lymphoblastic Leukemia
Acute Leukemia of Ambiguous Lineage
Adult Acute Myeloid Leukemia in Remission
Childhood Acute Lymphoblastic Leukemia in Remission

Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Drug: Fludarabine Phosphate
Other: Laboratory Biomarker Analysis
Drug: Methotrexate
Procedure: Peripheral Blood Stem Cell Transplantation
Biological: T Cell-Depleted Hematopoietic Stem Cell Transplantation
Drug: Tacrolimus
Drug: Thiotepa
Radiation: Total-Body Irradiation

First Posted Date: 2013-05-21

Last Posted Date: 2024-03-12

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 20

Registration Number: NCT01858740

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Prevention of Ovarian Cancer in Women Participating in Mammography

Not Applicable

Completed

Conditions: Epithelial Ovarian Cancer

Interventions: Behavioral: genetic counseling

First Posted Date: 2013-05-10

Last Posted Date: 2016-01-28

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 458

Registration Number: NCT01851109

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy